Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (934)	10/25/1999 11:04:00 PM
From: Cacaito	Respond to of 1386

Check the following link, is about BLA, but probably very similar to NDA (dexanabinol will be an NDA), pay special attention to the "surrogate" points: www3.techstocks.com, full document should be somewhere in FDA manuals. Decreasing intracranial pressure with sustained systemic pressure is a significant surrogate point, on top of that improvement in long term dissabilities will give dexanabinol good chances for approval. Decrease mortality will be a sure thing, but there are good chances even if just a trend is suggested plus above will give dexanabinol very good chances.

To: arnie h who wrote (934)	10/26/1999 5:41:00 AM
From: Stephen D. Wilson	Read Replies (1) \| Respond to of 1386

Arnie & Shadow If there is enough tax loss selling pressure to drop PARS below a dollor I find that would be just fine as a temporary situation. It would be a time to load up on more shares. I have already held this stock for almost 4 years. I have been in for the long term because I see a great potential. I have yet to load up on shares for the purpose of short term trading HOWEVER if PARS were to drop to below a dollar I believe that I would be loading up on it just for the short term trades. Steve